Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022

Euro Surveill. 2022 Jun;27(24):2200455. doi: 10.2807/1560-7917.ES.2022.27.24.2200455.

Abstract

We describe a gonorrhoea case with ceftriaxone plus high-level azithromycin resistance. In April 2022, an Austrian heterosexual male was diagnosed with gonorrhoea after sexual intercourse with a female sex worker in Cambodia. Recommended treatment with ceftriaxone (1 g) plus azithromycin (1.5 g) possibly failed. Worryingly, this is the second strain in an Asian Neisseria gonorrhoeae genomic sublineage including high-level azithromycin-resistant strains that developed ceftriaxone resistance by acquisition of mosaic penA-60.001. Enhanced resistance surveillance and actions are imperative to prevent spread.

Keywords: Neisseria gonorrhoeae; XDR; ceftriaxone resistance; extensively drug-resistant; high-level azithromycin resistance.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Austria
  • Azithromycin / pharmacology
  • Azithromycin / therapeutic use
  • Ceftriaxone / pharmacology
  • Ceftriaxone / therapeutic use
  • Drug Resistance, Bacterial / genetics
  • Female
  • Gonorrhea* / diagnosis
  • Gonorrhea* / drug therapy
  • Gonorrhea* / epidemiology
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Neisseria gonorrhoeae / genetics
  • Sex Workers*
  • Treatment Failure

Substances

  • Anti-Bacterial Agents
  • Ceftriaxone
  • Azithromycin